Ayala Pharmaceuticals (NASDAQ:ADXS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research note issued to investors on Monday morning. The brokerage issued a sell rating on the stock.

Ayala Pharmaceuticals Stock Performance

NASDAQ ADXS opened at $0.02 on Monday. Ayala Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $1.49. The stock has a market cap of $852,600.00, a P/E ratio of 0.00 and a beta of 1.55. The stock’s fifty day moving average price is $0.21 and its 200-day moving average price is $0.49.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.